Federal Register / Vol. 87, No. 73 / Friday, April 15, 2022 / Notices 22541 

Place: National Human Genome Research 

Institute, National Institutes of Health, 6700B 

Rockledge Drive, Suite 300, Bethesda, MD 

20892 (Virtual Meeting). 

Contact Person: Keith McKenney, Ph.D., 

National Human Genome Research Institute, 

National Institutes of Health, 6700B 

Rockledge Drive, Suite 300 Bethesda, MD 

20892, (301) 594–4280 mckenneyk@

mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.172, Human Genome 

Research, National Institutes of Health, HHS) 

Dated: April 12, 2022. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–08109 Filed 4–14–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Drug Abuse; 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The contract proposals and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the contract 

proposals, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; 

Synthesis and Distribution of Drugs of Abuse 

and Related Compounds. 

Date: May 9, 2022. 

Time: 1:00 p.m. to 2:00 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institutes of Health, 

National Institute on Drug Abuse, 301 North 

Stonestreet Avenue, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Marisa Srivareerat, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, Office of Extramural Policy, National 

Institute on Drug Abuse, NIH, 301 North 

Stonestreet Avenue, MSC 6021, Bethesda, 

MD 20892, (301) 435–1258, 

marisa.srivareerat@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.277, Drug Abuse Scientist 

Development Award for Clinicians, Scientist 

Development Awards, and Research Scientist 

Awards; 93.278, Drug Abuse National 

Research Service Awards for Research 

Training; 93.279, Drug Abuse and Addiction 

Research Programs, National Institutes of 

Health, HHS) 

Dated: April 11, 2022. 

Tyeshia M. Roberson-Curtis, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–08086 Filed 4–14–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; NIAID SBIR Phase II 

Clinical Trial Implementation Cooperative 

Agreement (U44 Clinical Trial Required). 

Date: May 25, 2022. 

Time: 12:00 p.m. to 2:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, Room 4F52, 

Rockville, MD 20892 (Virtual Meeting). 

Contact Person: Lindsey M. Pujanandez, 

Ph.D., Scientific Review Officer, Scientific 

Review Program, Division of Extramural 

Activities, National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, Room 4F52, 

Rockville, MD 20852, (240) 627–3206, 

lindsey.pujanandez@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: April 11, 2022. 

Tyeshia M. Roberson-Curtis, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–08087 Filed 4–14–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HOMELAND 

SECURITY 

Coast Guard 

[Docket No. USCG–2022–0159] 

National Maritime Security Advisory 

Committee; May 2022 Teleconference 

AGENCY: U.S. Coast Guard, Department 

of Homeland Security. 

ACTION: Notice of Federal Advisory 

Committee teleconference meeting. 

SUMMARY: The National Maritime 

Security Advisory Committee 

(Committee) will meet via 

teleconference, to review and discuss on 

matters relating to national maritime 

security, including on enhancing the 

sharing of information related to 

cybersecurity risks that may cause a 

transportation security incident, 

between relevant Federal agencies and 

(a) state, local, and tribal governments, 

(b) relevant public safety and emergency 

response agencies, (c) relevant law 

enforcement and security organizations, 

(d) maritime industry, (e) port owners 

and operators, and, (f) terminal owners 

and operators. This teleconference will 

be open to the public. 

DATES: 

Meetings: The Committee will meet 

by teleconference on Tuesday, May 3, 

2022 from 1 p.m. until 5 p.m. Eastern 

Daylight Time (EDT) and on 

Wednesday, May 4, 2022 from 9 a.m. to 

noon. This teleconference may close 

early if all business is finished. 

Comments and supporting 

documentation: To ensure your 

comments are received by Committee 

members before the teleconference, 

submit your written comments no later 

than April 22, 2022. 

ADDRESSES: To join the teleconference 

or to request special accommodations, 

contact the individual listed in the FOR

FURTHER INFORMATION CONTACT section 

no later than 1 p.m. EDT on April 22, 

2022, to obtain the needed information. 

The number of teleconference lines are 

limited and will be available on a firstcome, first-served basis. 

Instructions: You are free to submit 

comments at any time, including orally 

at the teleconference as time permits, 

but if you want Committee members to 

review your comment before the 

teleconference, please submit your 

comments no later than April 22, 2022. 

We are particularly interested in 

comments on the issues in the 

‘‘Agenda’’ section below. We encourage 

you to submit comments through 

Federal eRulemaking Portal at https://

regulations.gov. If your material cannot 


jspears on DSK121TN23PROD with NOTICES1